Secukinumab

GPTKB entity

Statements (55)
Predicate Object
gptkbp:instanceOf monoclonal antibody
gptkbp:administrativeDivision once a month after initial loading dose
gptkbp:approves gptkb:FDA
gptkbp:brand Cosentyx
gptkbp:clinicalTrials Phase III
FUTURE 1
FUTURE 2
FUTURE 3
MEASURE 1
MEASURE 2
active ankylosing spondylitis
active psoriatic arthritis
non-radiographic axial spondyloarthritis
MAXIMISE
chronic plaque psoriasis
gptkbp:contraindication inflammatory bowel disease
liver enzyme elevation
active infections
thrombocytopenia
hypersensitivity to the drug
neutropenia
serious infections
gptkbp:dosageForm solution for injection
gptkbp:drugInterdiction immunosuppressants
live vaccines
other biologics
gptkbp:endOfLife about 27 days
gptkbp:formulation auto-injector
pre-filled syringe
gptkbp:hasPopulation adults
https://www.w3.org/2000/01/rdf-schema#label Secukinumab
gptkbp:is_monitored_by liver function tests
complete blood count
signs of infection
gptkbp:issuedBy subcutaneous injection
gptkbp:lastProduced 2015
gptkbp:manufacturer Novartis
gptkbp:marketedAs gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:Japan
gptkb:United_States
gptkbp:numberOfStudents metabolized by the reticuloendothelial system
gptkbp:patentExpiration 2026
gptkbp:sideEffect fatigue
headache
nausea
injection site reactions
upper respiratory infections
gptkbp:storage refrigerated
gptkbp:targets IL-17A
gptkbp:triggerType neutralizes IL-17A
gptkbp:usedFor treatment of psoriasis
treatment of ankylosing spondylitis
treatment of psoriatic arthritis